Marché mondial des services de découverte de médicaments – Tendances et prévisions du secteur jusqu’en 2030

Analyse et taille du marché des services de découverte de médicaments

Selon l'American Cancer Society, environ 1,8 million de nouveaux cas de cancer ont été diagnostiqués en 2020, avec environ 606 520 décès par cancer aux États-Unis. Ainsi, le fardeau croissant des maladies et son fardeau mondial stimulent la demande de services de découverte de médicaments. Pour une meilleure identification des candidats médicaments, on a constaté une augmentation de l'utilisation de technologies avancées telles que la bioinformatique , le haut débit et la chimie combinatoire. Avec les technologies émergentes, la découverte de médicaments a considérablement évolué, rendant le processus plus raffiné, plus précis et plus long.

Français Data Bridge Market Research analyse que le marché des services de découverte de médicaments, qui était de 14,68 milliards USD en 2022, devrait atteindre 44,91 milliards USD d'ici 2030, à un TCAC de 15,00 % au cours de la période de prévision 2023 à 2030. En plus des informations sur les scénarios de marché tels que la valeur marchande, le taux de croissance, la segmentation, la couverture géographique et les principaux acteurs, les rapports de marché organisés par Data Bridge Market Research comprennent également une analyse approfondie des experts, l'épidémiologie des patients, l'analyse du pipeline, l'analyse des prix et le cadre réglementaire.

Portée et segmentation du marché des services de découverte de médicaments

Market Definition

Drug discovery is the process of identifying a compound that can be used to treat and cure diseases. A drug discovery effort typically addresses a biological target that has been shown to play a role in disease development or begins with a molecule with interesting biological activities. Drug discovery has recently evolved significantly as a result of emerging technologies, allowing the process to become more refined, accurate, and time-consuming.   Drugs were discovered by identifying the active ingredient in traditional remedies or by chance, as in the case of penicillin.

Global Drug Discovery Services Market Dynamics

Drivers

• Rising demand for novel therapies for various therapeutic purposes

Drug discovery services market growth is expected to be driven by rising demand for novel medicine for chronic diseases and development in the global healthcare sector. Pharmaceutical and biopharma companies continue to outsource their research and development activities to contract research organisations (CROs), which provides R&D services and develop engagement models to maximise R&D productivity. The rising burden of chronic diseases is compelling governments and pharmaceutical companies to seek solutions and increase investment in clinical trials. As a result, the demand for drug discovery services will increase.

• Rising chronic disease burden

Chronic conditions such as diabetes, dementia, and cardiovascular disease have high socioeconomic costs and a high and rising patient illness burden. They cause seven out of every ten fatalities worldwide, accounting for more than 40 million deaths yearly. Chronic diseases, which are the leading causes of death and disability in the United States, account for the majority of healthcare costs. As a result, the global market for drug discovery services is expected to be driven by the prevalence of chronic diseases over the forecast period, resulting in an increase in R&D spending and research activities for developing novel drugs. There is a high demand for medications due to the increased prevalence of these chronic diseases which creates new economic opportunities for companies that provide drug discovery services.

Opportunities

• Increasing spending on R&D activities

The biopharmaceutical industry's increased R&D spending is driving demand for clinical trial and analytical test outsourcing. The global drug discovery services market is being propelled forward by increased research efforts on orphan pharmaceuticals and uncommon research diseases. The growing demand for biopharmaceutical treatments is propelling the biologics industry forward globally. Biopharmaceuticals alone account for approximately 20% of the pharmaceutical industry. The development of numerous novels and effective life-saving biologics treatments has increased demand. Biologics companies are encouraged to invest in developing new drugs for a wide range of common and uncommon diseases. Furthermore, patent expiration and rising demand for biologics in emerging markets propel the global drug discovery services market.

Restraints/Challenges

• High cost of drug molecules

A lack of skilled labor and a high target drug molecule failure rate will be the major impediments to the market. The drug development costs are high as millions of dollars are spent in preclinical research to identify a compound or design a drug.

This drug discovery services market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the drug discovery services market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

COVID-19 Impact on the Drug Discovery Services Market

The SARS-sudden CoV-2's emergence and spread prompted international multilateral organizations and private funders to pool their resources to support the development of an effective vaccine to combat the coronavirus and its variants. Around the world, a large number of scientists, technologists, and data managers are involved in everything from laboratory investigations to clinical trials. The COVID-19 intervention has assisted the government and healthcare sectors in understanding the importance of drug discovery in developing effective medications. As a result, many businesses have increased their R&D spending, and the government has prioritized drug discovery and development, which positively impacts the market for drug discovery services.

Countries' health systems are rapidly investing in research and development to combat the COVID-19 pandemic. Potential compounds were selected from the CHEMBL, ZINC, FDA-approved drugs, and clinical trial molecules. Worldwide, research teams are identifying drugs for the treatment of COVID-19 by screening both novel and existing drugs for their ability to alleviate symptoms and halt viral replication. As a result of the ongoing pandemic, the drug discovery services market is expected to benefit from the desire to find a cure for COVID-19.

Recent developments

• On December 3, 2021, Toxikon Corporation, a contract research company, acquired by Labcorp. Toxikon's acquisition is expected to broaden the company's product portfolio.
• On January 25, 2022, Evotec and Boehringer Ingelheim formed a target and drug development collaboration focused on iPSC-based disease modelling for ophthalmologic illnesses.

Global Drug Discovery Services Market Scope

The drug discovery services market is segmented on the basis of type, process, drug type and therapeutic area. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Type

• Medicinal Chemistry Services
• Biology Services
• Drug Metabolism and Pharmacokinetics

Process

• Target Validation
• Target Selection
• Hit-To-Lead Identification
• Candidate Validation
• Lead Optimization

 Drug Type

• Biologics
• Small Molecules

 Therapeutic Area

• Neurology
• Diabetes
• Oncology
• Respiratory Diseases
• Cardiovascular Diseases
• Others

Drug Discovery Services Market Regional Analysis/Insights

The drug discovery services market is analysed and market size insights and trends are provided by country, type, process, drug type and therapeutic area as referenced above.

The countries covered in the drug discovery services market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America dominates the drug discovery services market because of the availability of cutting-edge techniques, instruments, and facilities for drug discovery research in this region due to many qualified researchers and low-cost operations in emerging countries such as India and China.

Asia-Pacific is expected to grow at the highest growth rate in the forecast period of 2023 to 2030 owing to the strong presence of well-established CROs, and rising R&D expenditure by pharmaceutical and biopharmaceutical companies.

La section pays du rapport fournit également des facteurs d'impact sur les marchés individuels et des changements de réglementation sur le marché national qui ont un impact sur les tendances actuelles et futures du marché. Des points de données tels que l'analyse de la chaîne de valeur en aval et en amont, les tendances techniques et l'analyse des cinq forces de Porter, les études de cas sont quelques-uns des indicateurs utilisés pour prévoir le scénario de marché pour les différents pays. En outre, la présence et la disponibilité des marques mondiales et les défis auxquels elles sont confrontées en raison de la concurrence importante ou rare des marques locales et nationales, l'impact des tarifs nationaux et les routes commerciales sont pris en compte tout en fournissant une analyse prévisionnelle des données nationales.

Analyse du paysage concurrentiel et des parts de marché des services de découverte de médicaments

Le paysage concurrentiel du marché des services de découverte de médicaments fournit des détails par concurrent. Les détails inclus sont la présentation de l'entreprise, les finances de l'entreprise, les revenus générés, le potentiel du marché, les investissements dans la recherche et le développement, les nouvelles initiatives du marché, la présence mondiale, les sites et installations de production, les capacités de production, les forces et les faiblesses de l'entreprise, le lancement du produit, la largeur et l'étendue du produit, la domination des applications. Les points de données ci-dessus fournis ne concernent que l'orientation des entreprises liée au marché des services de découverte de médicaments.

Certains des principaux acteurs opérant sur le marché des services de découverte de médicaments sont :

• General Electric (États-Unis)
• Eurofins Scientific (États-Unis)
• PPD Inc. (États-Unis)
• Syngene International Limited (Inde)
• Wuxi AppTec (Chine)
• Frontage Labs (États-Unis)
• Galapagos NV (Belgique)
• Aurigene Discovery Technologies (Inde)
• Genscript (États-Unis)
• Domainex (Royaume-Uni)
• WIL Research Laboratories LLC (États-Unis)
• Shanghai Medicilon, Inc. (Chine)
• Développement de médicaments Labcorp (États-Unis)
• Jubilant Biosys Ltd. (Inde)
• Evotec (Allemagne)
• Shanghai ChemPartner (Chine)
• Charles River Laboratories (États-Unis)
• Merck & Co. Inc. (États-Unis)
• Thermo Fisher Scientific Inc. (États-Unis) 

SKU-57114